Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Normosol-R and 5% Dextrose is a sterile, nonpyrogenic isotonic solution for intravenous administration, serving as a parenteral fluid, electrolyte, and nutrient replenisher. It contains a combination of magnesium chloride, potassium chloride, dextrose monohydrate, sodium gluconate, sodium chloride, and sodium acetate anhydrous. The solution is designed to provide water and essential electrolytes in a composition that approximates the principal ions of normal plasma, while the 5% dextrose component provides carbohydrate calories. It is indicated for the replacement of acute extracellular fluid losses and the maintenance of fluid and electrolyte balance in patients where oral intake is insufficient or contraindicated. The acetate and gluconate components act as bicarbonate precursors to help maintain acid-base balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Normosol-R and 5% Dextrose.